81
Participants
Start Date
December 15, 2021
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
Department of Hematology X, Odense University Hospital, Odense
Department of Hematology, Zeeland University Hospital Roskilde, Roskilde
Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki
Oulu University Hospital, Oulu
Department of Oncology, Haukeland University Hospital, Bergen
Avd. for Kreftbehandling, Oslo Universitetssykehus, Oslo
Avdeling for Blod- og Kreftsykdommer, Stavanger Universitetssykehus, Stavanger
Kreftklinikken, St Olavs Hospital, Trondheim
Division of Hematology-Oncology Samsung Medical Center Seoul, Seoul
Hematological Department, Falu Hospital, Falun, Falun
Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg
Department of Medicine, Halmstad Country Hospital, Halmstad
Department of Internal Medicine, Kalmar County Hospital, Kalmar
Hematologiska Kliniken, Universitetssjukhuset, Linköping
Department of Medicine, Sunderbyn Hospital, Luleå
Mats Jerkeman, Lund
Center of Hematology, Karolinska University Hospital, Stockholm
Uddevalla Hospital, Uddevalla
Cancercentrum, Norrlands Universitetsjukhus, Umeå
Department of Oncology, Uppsala Academic Hospital, Uppsala
Collaborators (1)
AstraZeneca
INDUSTRY
Nordic Lymphoma Group
NETWORK